Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor

Saumya S Gurbani; Brent D Weinberg; Eric Salgado; Alfredo Voloschin; Jose Enrique Velazquez Vega; Jeffrey J Olson; Hui-Kuo G Shu; Hyunsuk Shim

doi:10.1093/omcr/omaa006

Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor

Oxf Med Case Reports. 2020 Mar 30;2020(3):omaa006. doi: 10.1093/omcr/omaa006. eCollection 2020 Mar.

Authors

Saumya S Gurbani¹, Brent D Weinberg^{2

3}, Eric Salgado¹, Alfredo Voloschin^{3

4}, Jose Enrique Velazquez Vega⁵, Jeffrey J Olson^{3

6}, Hui-Kuo G Shu^{1

3}, Hyunsuk Shim^{1

2

3}

Affiliations

¹ Department of Radiation Oncology, Emory University, Atlanta, GA, USA.
² Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA.
³ Winship Cancer Institute, Emory University, Atlanta, GA, USA.
⁴ Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA.
⁵ Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.
⁶ Department of Neurosurgery, Emory University, Atlanta, GA, USA.

Abstract

Secondary glioblastoma is a rare brain tumor characterized by a mutation in isocitrate dehydrogenase, which is reported to lead to epigenetic modification. Patients with secondary glioblastoma experience poor survival and quality-of-life outcomes due to the disease's aggressiveness and a lack of targeted therapies. In this report, a patient with a secondary glioblastoma was treated with a histone deacetylase inhibitor, an epigenetic drug with potent anti-inflammatory properties, in addition to the standard regimen. The patient showed very favorable survival and quality-of-life measures, and a restoration of several neuro-metabolites as measured by spectroscopic magnetic resonance imaging.

Keywords: HDAC inhibitor.

Publication types

Case Reports

Abstract

Publication types

Grants and funding